|Bid||280.90 x N/A|
|Ask||280.90 x N/A|
|Day's range||273.75 - 285.90|
|52-week range||241.17 - 337.40|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||20 Sept 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||352.25|
The British economy has descended into turmoil after the Government’s mini-Budget triggered a historic rout in the bond market – but some investment experts think this has created buying opportunity at rock-bottom prices.
The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years
The company, which owns health products Sensodyne and Panadol, posted a 13.4% rise in its revenue to £5.2 billion in the first half of the year.